Literature DB >> 17470880

Vascular endothelial growth factor levels in immunodepleted plasma of cancer patients as a possible pharmacodynamic marker for bevacizumab activity.

Fotios Loupakis, Alfredo Falcone, Gianluca Masi, Anna Fioravanti, Robert S Kerbel, Mario Del Tacca, Guido Bocci.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17470880     DOI： 10.1200/JCO.2006.10.3051

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  26 in total

1.  Myeloid biomarkers associated with glioblastoma response to anti-VEGF therapy with aflibercept.

Authors:  John F de Groot; Yuji Piao; Hai Tran; Mark Gilbert; Hua-Kang Wu; Jun Liu; B Nebiyou Bekele; Tim Cloughesy; Minesh Mehta; H Ian Robins; Andrew Lassman; Lisa DeAngelis; Kevin Camphausen; Alice Chen; W K A Yung; Michael Prados; Patrick Y Wen; John V Heymach
Journal:  Clin Cancer Res       Date:  2011-06-01       Impact factor: 12.531

2.  Predictive and prognostic angiogenic markers in a gynecologic oncology group phase II trial of bevacizumab in recurrent and persistent ovarian or peritoneal cancer.

Authors:  Ernest S Han; Robert A Burger; Kathleen M Darcy; Michael W Sill; Leslie M Randall; Dana Chase; Basmina Parmakhtiar; Bradley J Monk; Benjamin E Greer; Patrick Connelly; Koen Degeest; John P Fruehauf
Journal:  Gynecol Oncol       Date:  2010-09-25       Impact factor: 5.482

3.  Anti-vascular endothelial growth factor antibody monotherapy causes destructive advanced periodontitis in rice rats (Oryzomys palustris).

Authors:  J G Messer; E J Castillo; A M Abraham; J M Jiron; R Israel; J F Yarrow; S Thomas; M C Reynolds; R D Wnek; M Jorgensen; N Wanionok; C Van Poznak; I Bhattacharyya; D B Kimmel; J I Aguirre
Journal:  Bone       Date:  2019-11-07       Impact factor: 4.398

4.  A phase I pharmacodynamic trial of sequential sunitinib with bevacizumab in patients with renal cell carcinoma and other advanced solid malignancies.

Authors:  Justine Yang Bruce; Jill M Kolesar; Hans Hammers; Mark N Stein; Lakeesha Carmichael; Jens Eickhoff; Susan A Johnston; Kimberly A Binger; Jennifer L Heideman; Scott B Perlman; Robert Jeraj; Glenn Liu
Journal:  Cancer Chemother Pharmacol       Date:  2014-01-12       Impact factor: 3.333

5.  Increase of plasma VEGF after intravenous administration of bevacizumab is predicted by a pharmacokinetic model.

Authors:  Marianne O Stefanini; Florence T H Wu; Feilim Mac Gabhann; Aleksander S Popel
Journal:  Cancer Res       Date:  2010-11-30       Impact factor: 12.701

6.  Myelosuppression of thrombocytes and monocytes is associated with a lack of synergy between chemotherapy and anti-VEGF treatment.

Authors:  Patrick Starlinger; Philipp Brugger; Dominic Schauer; Silvia Sommerfeldt; Dietmar Tamandl; Irene Kuehrer; Sebastian F Schoppmann; Michael Gnant; Christine Brostjan
Journal:  Neoplasia       Date:  2011-05       Impact factor: 5.715

7.  Soluble isoforms of vascular endothelial growth factor are predictors of response to sunitinib in metastatic renal cell carcinomas.

Authors:  Bernard Paule; Laurence Bastien; Emmanuelle Deslandes; Olivier Cussenot; Marie-Pierre Podgorniak; Yves Allory; Benyoussef Naïmi; Raphael Porcher; Alexandre de La Taille; Suzanne Menashi; Fabien Calvo; Samia Mourah
Journal:  PLoS One       Date:  2010-05-19       Impact factor: 3.240

8.  Total and not bevacizumab-bound vascular endothelial growth factor as potential predictive factors to bevacizumab-based chemotherapy in colorectal cancer.

Authors:  Amalia Azzariti; Letizia Porcelli; Oronzo Brunetti; Marzia Del Re; Vito Longo; Patrizia Nardulli; Michele Signorile; Jian-Ming Xu; Angela Calabrese; Anna Elisa Quatrale; Evaristo Maiello; Vito Lorusso; Nicola Silvestris
Journal:  World J Gastroenterol       Date:  2016-07-21       Impact factor: 5.742

9.  CD133+ circulating haematopoietic progenitor cells predict for response to sorafenib plus erlotinib in non-small cell lung cancer patients.

Authors:  L Vroling; J S W Lind; R R de Haas; H M W Verheul; V W M van Hinsbergh; H J Broxterman; E F Smit
Journal:  Br J Cancer       Date:  2009-12-15       Impact factor: 7.640

Review 10.  Biomarkers of angiogenesis and their role in the development of VEGF inhibitors.

Authors:  N Murukesh; C Dive; G C Jayson
Journal:  Br J Cancer       Date:  2009-12-15       Impact factor: 7.640
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.